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SUMMARY
Colorectal cancer is a leading cause of cancer-
related deaths. Mutations in the innate immune
sensor AIM2 are frequently identified in patients
with colorectal cancer, but how AIM2 modulates
colonic tumorigenesis is unknown. Here, we found
that Aim2-deficient mice were hypersusceptible to
colonic tumor development. Production of inflamma-
some-associated cytokines and other inflammatory
mediators was largely intact in Aim2-deficient mice;
however, intestinal stem cells were prone to
uncontrolled proliferation. Aberrant Wnt signaling
expanded a population of tumor-initiating stem cells
in the absence of AIM2. Susceptibility of Aim2-defi-
cientmice to colorectal tumorigenesiswas enhanced
by a dysbiotic gut microbiota, which was reduced by
reciprocal exchange of gut microbiota with healthy
wild-type mice. These findings uncover a synergy
between a specific host genetic factor and gutmicro-
biota in determining the susceptibility to colorectal
cancer. Therapeutic modulation of AIM2 expression
and microbiota has the potential to prevent colo-
rectal cancer.
INTRODUCTION
Colorectal cancer is a leading cause of cancer-related deaths,
with 160,000 cases being diagnosed annually in theUSA (Marko-
witz and Bertagnolli, 2009). Mutations in the gene encoding AIM2
are frequently identified in patients with colorectal cancer. A pre-
vious study has shown that more than 50% of tumors from pa-
tients with small bowel cancer have frameshift mutations in the
gene encoding AIM2 (Schulmann et al., 2005). Further genetic
evidence has shown that frameshift and missense mutations
are targeted to the coding regions of the gene encoding AIM2
in colon cancer tissues and cell lines (Kim et al., 2013; Woerner
et al., 2007). These include frameshift mutations in the A10
repeat of exon 6, a deletion mutation in the A6 repeat of exon
5, and a nonsynonymous nucleotide exchange within exon 2 of
the gene encoding AIM2—all of which were identified in tumor
tissues of patients with colorectal cancer with a high level of mi-
crosatellite instability associated with deficiency in mismatch
repair (Woerner et al., 2007). Analysis of 414 colorectal tumors
andmatching control tissues further revealed that 67% of the tu-
mors displayed reduced expression of the gene encoding AIM2
relative to control tissues (Dihlmann et al., 2014). Nearly 50% of
patients who completely lacked expression of the gene encod-
ing AIM2 in their tumor cells die from their cancer within 5 years
of diagnosis, whereas over 70% of patients whose tumor cells
retained some expression survived beyond 5 years after their
diagnosis (Dihlmann et al., 2014). A better understanding of the
biological function of AIM2 in colorectal cancer is key to identi-
fying therapies that could be used in the treatment of this
disease.
AIM2 is a cytosolic double-stranded DNA (dsDNA) receptor
that contributes to the host defense against bacterial and viral
pathogens, such as Francisella tularensis and vaccinia virus,
respectively (Bu¨rckstu¨mmer et al., 2009; Fernandes-Alnemri
et al., 2009; Fernandes-Alnemri et al., 2010; Hornung et al.,
2009; Rathinam et al., 2010; Roberts et al., 2009). We previously
identified that infection by the cytosolic bacterium Francisella
tularensis subspecies novicida activates the transcription factor
IRF1, which induces production of interferon-inducible GTPases
called guanylate-binding proteins (Man et al., 2015). Guanylate-
binding proteins attack and kill bacteria in the cytoplasm, result-
ing in the liberation of bacterial DNA for recognition by AIM2 (Man
et al., 2015; Meunier et al., 2015). Upon binding of dsDNA in the
cytoplasm of infected cells, AIM2 recruits the adaptor protein
ASC to assemble an inflammasome complex that activates
caspase-1, a cysteine protease that induces pyroptosis and
mediates the cleavage of the inflammatory cytokines IL-1b and
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Figure 1. AIM2 Prevents Colitis-Associated Colorectal Tumorigenesis
(A) Relative expression of the gene encoding AIM2 in tissues of WT C57BL/6 mice.
(B) Relative expression of the gene encoding AIM2 in colon tissues of untreated WT mice or WT mice 14 days after injection of AOM.
(C) Relative expression of the gene encoding AIM2 in colon tissues of untreated WT mice or WT mice 80 days after injection of AOM.
(D) Colon tumors in WT and Aim2–/– mice 80 days after injection of AOM.
(E and F) Number and size of colon tumors in WT (n = 34) and Aim2–/– (n = 27) mice.
(G) Body weight change of mice pooled from six independent experiments.
(legend continued on next page)
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IL-18. Structural analysis of AIM2 revealed that the HIN200
domain binds dsDNA, whereas the pyrin domain recruits ASC
(Jin et al., 2012). DNA accumulated in keratinocytes also acti-
vates the AIM2 inflammasome to drive the release of IL-1b in
lesions of patients with psoriasis (Dombrowski et al., 2011), sug-
gesting that AIM2 has the capacity to recognize damage-associ-
ated molecular patterns released by the cell. Activation of AIM2
must, therefore, be tightly regulated to allow clearance of patho-
gens while maintaining homeostasis to prevent the development
of autoimmune conditions.
In this study, we found that AIM2-deficient (Aim2–/–) mice
developed more tumors in the colon following azoxymethane
(AOM)- and dextran sulfate sodium (DSS)-induced colitis-asso-
ciated tumorigenesis. Unlike its role in the host defense against
infection, AIM2 protected against tumorigenesis by controlling
intestinal epithelial cell proliferation via a mechanism indepen-
dent of inflammasomes and inflammatory mediators. Upon
dysregulated Wnt signaling, AIM2 suppressed expansion of
tumor-initiating intestinal stem cells lining the base of the crypt.
Remarkably, reciprocal exchange of the gut microbiota between
healthy WT mice and Aim2–/– mice reduced the susceptibility of
Aim2–/– mice to colorectal tumorigenesis. These findings re-
vealed a role for AIM2 and its synergy with gut microbiota in
the development of colorectal cancer.
RESULTS
The DNA Receptor AIM2 Is Required to Prevent
Colorectal Cancer
Mutations in the gene encoding AIM2 are associated with colo-
rectal cancer, and reduced expression of this gene is linked to
increased mortality in humans (Dihlmann et al., 2014; Kim
et al., 2013; Schulmann et al., 2005; Woerner et al., 2007).
In mice, the gene encoding AIM2 was widely expressed in the
intestine, especially in the colon (Figure 1A), which suggested
a role for AIM2 in regulating homeostasis in the gastrointestinal
tract. To investigate the role of AIM2 in colorectal cancer, we
used an established model of colitis-associated colorectal
tumorigenesis whereby mice were injected intraperitoneally
with AOM, followed by three rounds of DSS treatment (Fig-
ure S1A). Expression of the gene encoding AIM2 was drastically
reduced in the colon of WT mice 14 or 80 days after injection of
AOM (Figures 1B and 1C). Reduced expression of the gene en-
coding AIM2 was also observed in tumor tissues isolated from
patients with colorectal cancer compared with non-tumor tis-
sues (Figure S1B).
We treated cohorts ofWT andAim2–/– micewith AOM followed
by DSS and examined the development of colon tumors after
80 days. We found that Aim2–/– mice developed significantly
increased numbers and size of tumors throughout the middle
and distal colon compared with WT mice (Figures 1D–1F).
Aim2–/– mice also tended to lose more body weight over the
course of DSS treatment after injection of AOM (Figure 1G). His-
topathological analysis revealed that Aim2–/– mice exhibited
increased hyperplasia in the proximal, middle, and distal colon
(Figure 1H). Low-grade dysplasia was restricted to tumor-
bearing WT mice, whereas both low- and high-grade dysplasia
was observed in Aim2–/– mice (Figures 1I and 1J). These results
suggested that AIM2 mediated protection against colorectal
tumorigenesis.
AIM2 Controls Tumor Development Independently of
Inflammasomes
AIM2 is a dsDNA receptor that contributes to the host defense
against bacterial and viral pathogens by inducing inflammasome
responses, including the production of IL-18. We and others
have previously shown that IL-18 induced by the related inflam-
masome, NLRP3 inflammasome, is required for protection
against colitis and colitis-associated tumorigenesis (Allen et al.,
2010; Zaki et al., 2010a; Zaki et al., 2010b). To investigate the
molecular mechanism underpinning AIM2-dependent protection
against colorectal tumorigenesis, we first examined whether
there was a lack of inflammasome signaling in Aim2–/– mice
that could be responsible for their increased susceptibility to
tumorigenesis. We analyzed the levels of caspase-1 processing
in the colon of WT and Aim2–/– mice and found similar levels of
caspase-1 activation 14 days after injection of AOM (Figure 2A).
We also detected similar levels of IL-18 in the colon tissues and
sera of untreatedWT andAim2–/– mice or inWT andAim2–/– mice
8, 14, or 80 days after injection of AOM (Figure 2B). To further
confirm these results, we measured IL-1b and found similar
levels of this inflammasome-dependent cytokine in the colon tis-
sues of untreated WT and Aim2–/– mice or in WT and Aim2–/–
mice 14 or 80 days after injection of AOM (Figure 2C).
Although AIM2 functioned independently of the inflamma-
some in protection against colonic tumorigenesis, we investi-
gated whether other inflammatory mediators might be playing
a role in the absence of AIM2 that could have accelerated the
progression of colorectal cancer. Shortening of the colon during
DSS treatment is a hallmark of inflammation. However, we
observed similar colon lengths in WT and Aim2–/– mice 14 or
80 days after injection of AOM (Figure 2D). The NF-kB pathway
is a major driver of inflammation. To this end, we analyzed phos-
phorylation of extracellular signal-regulated kinase (ERK) and
IkBa in colon tissues of WT and Aim2–/– mice following AOM-
DSS treatment. Both groups of mice exhibited similar levels of
phosphorylated ERK and IkBa (Figure 2E). In agreement, the
levels of pro-inflammatory cytokines IL-6, tumor-necrosis factor
(TNF), and granulocyte colony-stimulating factor (G-CSF) and
the chemokine CXCL1 (KC) were not significantly increased in
Aim2–/– mice 14 days after injection of AOM when compared
with WT mice (Figure 2F). However, an increase in the levels of
TNF, G-CSF, and KC was observed 80 days after injection of
AOM (Figure 2F). We further assessed the levels of cytokines
(H) Histological scores 80 days after injection of AOM.
(I) Percentages of mice with dysplasia 80 days after injection of AOM.
(J) H&E staining of colon tumors. Original magnification, (J) 103.
Each symbol represents an individual mouse (E andH). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; NS, not statistically significant (two-tailed t test [B, C, E, F,
and H] or one-way ANOVA [G]). Data represent two (A–C) or six independent experiments (D–J; mean and SEM in B, C, E, F, G, and H). See also Figure S1.
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Figure 2. AIM2 Governs Colorectal Tumorigenic Susceptibility Independently of Inflammasomes and a Number of Inflammatory Mediators
(A) Caspase-1 processing in colon lysates from WT and Aim2–/– mice 14 days after injection of AOM.
(B) Levels of IL-18 in the colon tissues and sera.
(C) Levels of IL-1b in colon tissues.
(D) The lengths of colon from WT and Aim2–/– mice 14 days after injection of AOM.
(legend continued on next page)
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IL-22, IL-23p19, IFN-b, IFN-g, and IL-17A. Using qRT-PCR anal-
ysis, we found that the expression of genes encoding these
cytokines was similar in colon tissues of untreated WT and
Aim2–/– mice and in colon tissues of WT and Aim2–/– mice
14 days after injection of AOM (Figures S2A and S2B). However,
Aim2–/– mice had an increase in the expression of genes encod-
ing IL-10 14 days after injection of AOM (Figure S2C). Further-
more, we found that the expression of genes encoding TGF-b1
and TGF-b2 was similar in colon tissues of untreated WT and
Aim2–/– mice and in WT and Aim2–/– mice 14 days after injection
of AOM (Figure S2C).
We used an automated hematology analyzer to determine the
number and influx of circulating white blood cells from the pe-
ripheral blood of WT and Aim2/ mice. We observed similar
levels of neutrophils, lymphocytes, monocytes, eosinophils,
and basophils and total white blood cells in the blood of WT
and Aim2/ mice 14 or 80 days after injection of AOM (Fig-
ure S2D). Although there was an increase in circulating lympho-
cytes in Aim2/ mice on day 80 compared with day 14, the
proportion of IFN-g-, IL-17-, or TNF-expressing CD4+ or CD8+
T cells in the MLNs and spleens was similar in WT and Aim2–/–
mice (Figure 2G). In addition, the prevalence of splenic and
MLN-associated CD11b+ cells producing TNF or IL-6 was also
similar in WT and Aim2–/– mice (Figure 2G). The prevalence of
total CD11b+ cells was, however, elevated in the spleen, but
not in the MLN. The modest increases in some inflammatory
parameters in mice lacking AIM2 suggested a role for an immu-
nological component in shaping tumor development in these
mice. Identification of a role for AIM2 independently of classical
inflammasome signaling and a number of other inflammatory
mediators also suggested, at least in part, alternative functions
for AIM2 in the regulation of gastrointestinal homeostasis during
colorectal tumorigenesis.
AIM2 Controls Proliferation of Enterocytes
Given that the increased susceptibility to tumor development in
Aim2–/– mice could not be explained by differences in inflamma-
some activity or by a number of inflammatory mediators, we
asked whether AIM2 regulated cellular proliferation or death
following exposure to AOM and DSS. We used immunohisto-
chemistry techniques to identify proliferative cells in the colon
ofWT andAim2–/– mice.We observed a significantly higher num-
ber of BrdU+ proliferative cells per crypt in the colon of Aim2–/–
mice 14, but not 8, days after injection of AOM (Figure 3A). We
confirmed these findings and found a significantly higher number
of Ki67+ cells per crypt in the intestinal epithelium ofAim2–/– mice
14 days after injection of AOM compared withWTmice, whereas
no difference was observed in untreated WT and Aim2–/– mice
(Figure 3A). Further, we used microarray analysis to screen for
genes expressed differentially in colon tissues of WT and
Aim2–/– mice 14 days after injection of AOM. Using this
approach, we indeed identified increased expression of genes
encoding molecules involved in cell proliferation in Aim2–/–
mice relative to their expression in WT mice (Figure 3B). These
included genes encoding S100A9 and BIRC5, which have previ-
ously been linked to colorectal carcinoma in humans (Bonte
et al., 2008; Vonlanthen et al., 2014; Zhao et al., 2010). We
confirmed, using qRT-PCR analysis, an increased expression
of the top three differentially expressed genes encoding mole-
cules involved in proliferation, S100A9, SNRPD1, and DBF4,
identified in our microarray (Figure 3C).
To further investigate the mechanism of unchecked cellular
proliferation when AIM2 was absent, we examined activities of
the phosphatidylinositol 3-Kinase–AKT pathway, which has a
major role in cell proliferation and survival and in development
of cancer (Vivanco and Sawyers, 2002). We found increased
phosphorylation of AKT at Ser473 in Aim2–/– mice compared
with WT mice 14 days after injection of AOM (Figure 3D), indi-
cating activation of the AKT pathway. Phosphorylation of AKT
at Ser473 was similar between WT and Aim2–/– mice 80 days
after injection of AOM (Figure 3D). The phosphatidylinositol
3-Kinase-AKT pathway is negatively regulated by the tumor
suppressor PTEN (Stambolic et al., 1998). Phosphorylation of
PTEN at S380, T382, and T383 maintains PTEN in a relatively
inactive state (Vazquez et al., 2000). Indeed, we saw increased
phosphorylation of PTEN at S380, T382, and T383 in Aim2–/–
mice compared with WT mice 14 days after injection of AOM
(Figure 3D).
Increased AKT activation and transcription of genes involved
in cell proliferation could explain increased proliferation in the
colon of mice lacking AIM2 following damage induced by
AOM. Consistent with increased AKT activation, we found an
elevated level of the transcription factor and proto-oncogene
c-Myc in Aim2–/– mice compared with WT mice 14 and
80 days after injection of AOM (Figure 3E). Expression of the tran-
scription factor HIF1-a, however, was similar between WT and
Aim2–/– mice (Figure 3E). We further confirmed by qRT-PCR
analysis an increased expression of the gene encoding c-Myc
(Figure 3F). In addition, increased intestinal cell proliferation
was linked to reduced apoptosis because the levels of cas-
pase-3 and caspase-7 activation in the colon of Aim2–/– mice
decreased compared with that in WT mice (Figures 3G and
3H). To examine possible intrinsic defects in the mucus layer in
mice lacking AIM2, we analyzed the thickness of themucus layer
and the expression of genes encoding mucin, MUC2, MUC3,
and MUC4, in WT and Aim2–/– mice. We found that the thickness
of the mucus layer lining the large intestine and the expression
levels of genes encoding MUC2, MUC3 and MUC4 were similar
(E) Immunoblot analysis (left) and densitometric quantification of band intensity of phosphorylated and total ERK and IkBa (right) in colon tissues of WT and
Aim2–/– mice 14 days after injection of AOM.
(F) Levels of IL-6, TNF, G-CSF, and KC in colon tissues.
(G) Percentages of CD4+ cells, CD4+ cells expressing IFN-g or IL-17, CD8+ cells, CD8+ cells expressing IFN-g, CD11b+ cells, and CD11b+ cells expressing IL-6
or TNF.
Each symbol represents an individual mouse (B–D, F, and G). *p < 0.05; **p < 0.01; NS, not statistically significant (two-tailed t test [B–D, F, andG]). Data represent
one experiment representative of two independent experiment (A–C andG) or pooled from three independent experiments (D–F; mean and SEM in B–G). See also
Figure S2.
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Figure 3. AIM2 Suppresses Overt Proliferation
(A) Quantification of the number of BrdU+ cells in each crypt of WT (day 8, n = 3; day 14, n = 5) and Aim2–/– (day 8, n = 4; day 14, n = 5) mice. Quantification of the
number of Ki67+ in each crypt of WT (day 0, n = 4; day 14, n = 4) and Aim2–/– (day 0, n = 3; day 14, n = 4) mice.
(B) Microarray analysis of genes encodingmolecules involved in proliferation with significantly higher or lower expression inAim2–/– mice 14 days after injection of
AOM compared with their WT counterparts.
(C) Real-time qRT-PCR analysis of genes encoding S100A9, SNRPD1, and DBF4 in WT and Aim2–/– mice 14 days after injection of AOM.
(legend continued on next page)
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in WT and Aim2–/– mice (Figures S3A and S3B). In addition, we
quantified the number of goblet cells and observed similar
numbers of these cells in the crypts of WT and Aim2–/– mice
(Figure S3C).
AIM2 Controls Expansion of Intestinal Stem Cells
We and others have previously identified intestinal stem cells as
the ‘‘cell-of-origin’’ of intestinal cancer (Barker et al., 2009; Zhu
et al., 2009). We hypothesized that the dramatic increase in
cell proliferation and tumor formation in Aim2–/– mice was
caused by a population of intestinal stem cells that is susceptible
to oncogenic insults. To investigate this, we cultivated and
measured the growth rate of stem cells harvested from the
colonic epithelia of untreatedWT and Aim2–/– mice. Remarkably,
colonic epithelial stem cells harvested from Aim2–/– mice consis-
tently formed more organoids over 5 days compared with those
harvested fromWTmice (Figure 4). In addition, we measured the
diameters of these organoids and found that a greater proportion
of organoids originated from Aim2–/– mice with a larger size
compared with those isolated from WT mice (Figure 4). These
data indicated that stem cells derived from the colon of
Aim2–/– mice exhibited an increased capacity to proliferate.
We and others have previously demonstrated that stem cells
or progenitor cells in the small intestine of mice are highly sus-
ceptible to tumorigenesis induced by aberrant activating b-cate-
nin mutations (Snippert et al., 2009; Zhu et al., 2009). These cells
are marked by Prom1 (CD133), a marker of cancer stem cells in
human intestinal tumors that arise as a result of aberrant wing-
less-int (Wnt) signaling (Bienz and Clevers, 2000; Sparks et al.,
1998). To investigate the role of AIM2 in this pathway, we used
the Prom1CreERT2-LacZ (C-L)/+; Ctnnb1lox(ex3)/+; RosaZsGreen
mouse strain to investigate proliferation of Prom1+ cells following
aberrant Wnt signaling (Zhu et al., 2009). The Prom1C-L/+ mouse
strain contains an inducible Cre and a nuclear LacZ reporter
allele knocked into the Prom1 locus, which allowed us to detect
cells expressing Prom1 using b-galactosidase staining. This
mouse strain also encodes a Cre-dependent RosaZsGreen re-
porter allele for use in lineage tracing, which is expressed irre-
versibly in Prom1+ cells when CreERT2 is induced from the
Prom1C-L/+ locus following tamoxifen treatment. Further, the
Wnt signaling pathway is aberrant in this mouse strain owing to
the presence of a Cre-dependent mutant allele of b-catenin
(Ctnnb1lox(ex3)). To determine whether colon cells from mice
lacking AIM2 exhibited increased tumor susceptibility to
Wnt signaling, we crossed Aim2–/– mice to Prom1C-L/+;
Ctnnb1lox(ex3)/+; RosaZsGreen mice.
We used b-galactosidase staining to detect nuclear LacZ
expression from the Prom1 promoter. We found that a loss of
(D) Immunoblot analysis of phosphorylated and total AKT and phosphorylated and total PTEN from colon tissues.
(E) Immunoblot analysis of c-Myc, HIF1-a and GAPDH (loading control) from colon tissues.
(F) Real-time qRT-PCR analysis of the gene encoding c-Myc in colon tissues of mice 14 days after injection of AOM.
(G and H) Immunoblot analysis of caspase-3 (G) and caspase-7 activation (H) in colon tissues of mice 8 days after injection of AOM.
At least 20 crypts were counted in each animal (A). Each symbol represents one crypt (A) or onemouse (C and F). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001;
NS, no statistical significance (two-tailed t test [A, C, and F]). Data represent one experiment with two biological replicates per genotype (B) or from one
experiment representative of two independent experiments (A, C, and D–H) (mean and SEM in A, C, and F). See also Figure S3.
Figure 4. AIM2 Controls Proliferation of Intestinal Progenitor Stem Cells
Formation of organoids derived from colonic stem cells harvested from untreated WT and Aim2–/– mice. Quantification of the number (top right) and size of
organoids (bottom right). Scale bars, 50 mm (left) or 200 mm (right). Data represent one of three independent experiments.
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AIM2 did not alter Prom1 expression pattern in the large intes-
tine, and the majority of cells in the colonic crypts expressed
Prom1 (Figure S4A). Remarkably, 3 weeks after induction of
aberrant b-catenin activation by tamoxifen treatment, we
observed a significant increase in the stem cell activity of
Prom1+ cells, indicated by GFP lineage tracing using the
RosaZsG allele in the colon of Prom1C-L/+; Ctnnb1lox(ex3)/+;
RosaZsG; Aim2–/– mice compared with Prom1C-L/+;
Ctnnb1lox(ex3)/+; RosaZsG; Aim2+/+ mice (Figure 5A). There was
a significantly increased number of GFP+ cells in Prom1C-L/+;
Ctnnb1lox(ex3)/+; RosaZsG; Aim2–/– mice relative to Prom1C-L/+;
Ctnnb1lox(ex3)/+; RosaZsG; Aim2+/+ mice (Figure S4B). GFP+ cells
populated almost the entire crypts inProm1C-L/+; Ctnnb1lox(ex3)/+;
RosaZsG; Aim2–/– mice (Figure 5A). We observed very few crypts
that were composed of GFP+ cells inProm1C-L/+; Ctnnb1lox(ex3)/+;
RosaZsG; Aim2+/+ mice (Figure 5A), indicating that a small pop-
ulation of Prom1+ cells could still potentially behave as stem or
progenitor cells in the colon of Aim2+/+ mice. These findings sug-
gested that the lack of AIM2 increased the stem cell activity of
Prom1+ cells following aberrant Wnt activation.
Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG mice succumb within
6 weeks of tamoxifen induction owing to extensive tumor forma-
tion initiated from Prom1+ stem cells in the small intestine (Fig-
ure 5B). Although we did not observe macroscopic tumors in
the large intestine of these animals, we found an elevated num-
ber of Ki67+ cells, increased staining for phosphorylated AKT,
total AKT and c-Myc, and a small number of abnormal crypts
in the large intestine of Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG;
Aim2–/– mice compared with Prom1C-L/+; Ctnnb1lox(ex3)/+;
RosaZsG; Aim2+/+ mice (Figures 5A and S4C). We also noticed
accelerated tumorigenesis, increased staining for phosphory-
lated and total AKT, and c-Myc in the small intestine of
Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2–/– mice compared
with Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2+/+ mice (Fig-
ure 5B). These results validated the colitis-associated colorectal
cancer model and suggested that AIM2 played a role in protect-
ing tumor formation in the intestine. Overall, loss of AIM2 resulted
in an increased stem cell activity in the colon following aberrant
Wnt-signaling in the intestinal stem-cell niche.
To further confirm a role for the epithelial compartment in
AIM2-mediated protection against colon cancer development,
we performed bone marrow transplantation experiments to
examine the contribution of the radio-resistant stromal compart-
ment relative to that of the hematopoietic compartment in gov-
erning colon tumorigenesis. As expected, Aim2–/– mice, which
received Aim2–/– bone marrow, were more susceptible to tumor-
igenesis compared to WT mice, which received WT bone
marrow (Figure 6A). After 80 days post-AOM injection, Aim2–/–
mice, which received WT bone marrow, had significantly
increased tumor burden compared to WT mice, which received
WT bone marrow (Figures 6B and 6C). These results provided
evidence to suggest that AIM2 in the stromal compartment could
play a role in the protection against colorectal tumorigenesis. WT
mice, which received Aim2–/– bone marrow also showed slightly
increased tumor compared with WT mice, which received WT
bone marrow, suggesting that bone marrow compartment
contributed to colorectal tumorigenesis via a yet-undefined
mechanism.
AIM2 Protects Colorectal Tumorigenesis by Modulating
the Gut Microbiota
Intestinal cell proliferation and the development and progression
of colorectal cancer is regulated by the composition of gut mi-
crobiota. Studies have reported that the NOD-like receptor pro-
tein NLRP6 modulates the microbial ecology and protects
against colon tumor development (Elinav et al., 2011; Normand
et al., 2011). To assess whether the gut microbiota plays a role
in the increased tumorigenic susceptibility of Aim2–/– mice, we
performed 16S rRNA gene sequencing analysis of the gut micro-
biota derived from stool samples of separately housed WT and
Aim2–/– mice. Our 16S rRNA gene sequencing analyses revealed
a markedly distinct intestinal microbial landscape in separately
housed WT and Aim2–/– mice (Figures 7A and 7B). Relative to
WT mice, Aim2–/– mice harbored increased levels of Akkerman-
sia muciniphila and Anaeroplasma and decreased levels of
Anaerostipes, Bifidobacterium, Flexispira, Prevotella, and Para-
prevotella species (Figure 7A). Of these, previous reports have
linked an increase in Akkermansia and a decrease in Prevotella-
ceae with the development of colonic tumorigenesis (Zackular
et al., 2013). Interestingly, co-housing equilibrated the relative
abundance of Anaerostipes, Flexispira, Prevotella, and Parapre-
votella in WT and Aim2–/– mice (Figures 7A and 7B).
We took advantage of the transmissible nature of the gut
microbiota to investigate whether susceptibility to colorectal
tumorigenesis could be reduced in Aim2–/– mice by co-housing
them with WT mice. Although we observed no major difference
in body weight between single-housed or co-housed WT and
Aim2–/– mice during AOM-DSS treatment (Figure S5), we found
a striking reduction in the number and incidence of colon tumors
in co-housed Aim2–/– mice compared with separately housed
Aim2–/– mice (Figures 7C and 7D). Intriguingly, WT mice co-
housed with Aim2–/– mice responded conversely and developed
more tumors compared with their separately housed controls
(Figures 7C and 7D). Co-housed Aim2–/– mice were still more
susceptible to tumorigenesis compared with co-housed WT
mice (Figures 7C and 7D), supporting the concept that both ge-
netic and environmental factors contributed to the development
of cancer.
DISCUSSION
Members of the pattern-recognition receptor family are central
players in the regulation of infectious, inflammatory, and meta-
bolic diseases. Our laboratory and others have previously shown
that the innate immune receptors NLRP3, NLRP6, NLRP12,
NLRC4, STING, and NOD2 are required for the protection
against colitis and colitis-associated tumorigenesis (Allen et al.,
2010; Allen et al., 2012; Elinav et al., 2011; Hu et al., 2010; Nor-
mand et al., 2011; Watanabe et al., 2008; Zaki et al., 2010a; Zaki
et al., 2010b; Zaki et al., 2011; Zhu et al., 2014). However, the role
of AIM2-like receptors, including AIM2 and IFI16 or p202, in
regulating gastrointestinal health and disease is unknown.
The innate immune receptor AIM2 was originally isolated from
human melanoma cells (DeYoung et al., 1997). AIM2 directly
binds dsDNA and initiates the recruitment of ASC and cas-
pase-1 to assemble a multi-protein inflammasome complex.
Whether AIM2 can operate independently of inflammasomes in
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AB
Figure 5. AIM2 Controls Expansion of Intestinal Stem Cells
(A) Lineage tracing (left) of Prom1+ cells (green) in the large intestine 3 weeks post-tamoxifen (TMX) induction. Blue staining indicates DAPI. Scale bar, 100 mm.
Staining for phosphorylated AKT (p-AKT, Ser473), total AKT and c-Myc (right) in the large intestine 6 weeks post-TMX induction. Scale bar, 200 mm. Arrowheads
indicate early lesions with intense staining for the respective markers.
(B) H&E staining and staining for p-AKT (Ser473), total AKT, c-Myc, and Ki67 staining in the small intestine 6 weeks post-TMX induction. Scale bars, 250 mm (H&E)
and 100 mm (p-AKT, total AKT, c-Myc, and Ki67 staining).
See also Figure S4.
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the cell is unclear. Here, we identified an unexpected function for
AIM2 that departs from its known role in inflammasome
signaling. Certain members of the NLR family, including NLRP6
and NLRP12, have also been shown to exert inflammasome-
dependent and inflammasome-independent functions in health
and disease (Man and Kanneganti, 2015).
The mechanism driving AIM2-dependent protection against
tumorigenesis is the ability of AIM2 to tightly suppress overt
cellular proliferation of intestinal epithelial cells. Whether AIM2
directly interacts with and prevents phosphorylation of the ki-
nase AKT is unclear. Unlike the role for NLRP6 in targeting goblet
cell mucin secretion (Wlodarska et al., 2014), AIM2 specifically
controlled expansion and proliferation of intestinal stem cells.
The larger population of cells derived from Prom1+ cells lining
the intestinal crypt in mice lacking AIM2 following aberrant in-
duction of b-catenin indicated that these cells might be highly
proliferative and less well differentiated. In vitro studies have
shown that ectopic expression of AIM2 can be used to promote
cell-cycle arrest and inhibition of cell proliferation (Patsos et al.,
2010). These findings, together, highlight the dynamic roles of
A
B
C
Figure 6. The Role of Hematopoietic
and Non-hematopoietic Compartments in
AIM2-Mediated Protection of Colorectal
Tumorigenesis
(A) Four groups of mice were generated by bone
marrow transplantation: (1) WT / WT, n = 9;
(2) Aim2–/–/WT, n = 9; (3) WT/ Aim2–/–, n = 7;
(4) Aim2–/–/Aim2–/–, n = 8. 6 weeks following
bone marrow transplantation, mice were treated
with AOM followed by DSS, and colon tumors
were counted 80 days after injection of AOM. The
numbers of tumors in the colon and percentages of
tumors of less than 2 mm or 2–4 mm in diameter
were quantified.
(B) Representative images of colon tumors.
(C) Representative H&E images of colon tumors.
Magnification: 203. Each symbol in the graph
represents one mouse (A). Data represent one
experiment (mean and SEM). *p < 0.05; **p < 0.01;
***p < 0.001. One-way ANOVA (A).
AIM2 in regulating cell functions during
cell growth and tumorigenesis.
In mice exposed to AOM-DSS, the
expression of AIM2 was downregulated
as early as 14 days, suggesting that
robust AIM2 expression was critical for
preventing early tumorigenic events. The
levels of AIM2 expression in tumor tissues
of patients have been shown to greatly in-
fluence the outcome of the disease.
Patients who have tumor cells that
completely lacked AIM2 expression
have a more than 3-fold higher mortality
rate than patients whose tumor cells re-
tained some AIM2 expression (Dihlmann
et al., 2014). The precise molecular signal
that triggers downregulation of AIM2
expression during colorectal tumorigenesis is unknown, and
therapeutic strategies aimed at increasing colonic AIM2 expres-
sion may help to prevent overt tumorigenesis in susceptible
individuals.
Of particular clinical relevance is the observation that defective
AIM2 function leading to tumorigenesis can be partially pre-
vented by a transmissible gut microbiota in cohoused mice.
This finding indicates that engraftment of healthy donor gut mi-
crobiota to patients suffering chronic intestinal inflammation
could reduce the risk of developing colorectal cancer. The mi-
crobiota plays a central role in modulating cell proliferation in
the intestine. Gut-associated Lactobacillus murinus enhances
cell proliferation in the mouse intestine (Okada et al., 2013).
Furthermore, gut microbiota has the capacity to induce IL-17C
production in intestinal epithelial cells via a MyD88-dependent
pathway, which leads to increased expression of the prosurvival
proteins Bcl2 and Bcl-xL to drive colorectal tumorigenesis (Song
et al., 2014). Carbohydrate-derived metabolites generated by
gut microbiota have also been shown to enhance colon epithelial
cell proliferation in an APCMin/+ mouse model lacking the gene
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encoding the DNA mismatch repair protein MutS homolog 2
(MSH2) (Belcheva et al., 2014).
During barrier damage, it is possible that DNA from microbial
species that have invaded intestinal cells or DNA from dying
host cells could be sensed by AIM2 in intestinal cells. It is
tempting to hypothesize that, instead of contributing to inflam-
matory response further by inducing activation of the inflamma-
some, AIM2 responds by dampening cellular proliferation in the
intestine. How AIM2 might be sensing different environmental
cues in the cytoplasm to direct context-specific cellular pro-
cesses is an exciting question for future investigation. In conclu-
sion, our findings demonstrated a requirement for AIM2 in the
protection against colorectal cancer. Therapeutic modulation
of AIM2 expression and gut microbiota could play a central
role in reducing the risk of developing colorectal cancer.
EXPERIMENTAL PROCEDURES
Mice
WT (C57BL/6), Aim2–/–, Asc–/–, Casp1–/–Casp11–/–, Casp3–/–, Casp7–/–, and
Prom1C-L/+;Ctnnb1lox(ex3)/+ mice were described previously (Harada et al.,
1999; Jones et al., 2010; Lakhani et al., 2006; Mariathasan et al., 2004; Zhu
et al., 2009). Prom1C-L/+;Ctnnb1lox(ex3)/+ mice were bred with Aim2–/– mice to
generate Prom1C-L/+;Ctnnb1lox(ex3)/+ Aim2–/– mice. RosaZsGreen reporter
mice were obtained from the Jackson Laboratory (Stock Number: 007906).
Mice were maintained in a specific pathogen-free facility. Animal study proto-
cols were approved by St. Jude Children’s Research Hospital Committee on
Use and Care of Animals.
Induction of Tumors
For the AOM and DSSmodel (Figure S1A), mice were injected intraperitoneally
with 10 mg of AOM (Sigma) per kg body weight. Five days later, 3% DSS (mo-
lecular mass 36–40 kDa; MP Biologicals) was given in the drinking water for
6 days followed by regular drinking water for 2 weeks. This cycle was repeated
A B
C D
Figure 7. Reciprocal Exchange of Gut Micro-
biota Reduces Susceptibility of Aim2–/– Mice
to Colon Cancer
(A) Bacterial species from feces that had the
greatest difference in abundance between single
housed WT and Aim2–/– mice and their relative
abundance in co-housed WT and Aim2–/– mice,
based on analysis of the 16S rRNA gene, are shown
in a heatmap in alphabetical order.
(B) Principal component analysis of (A).
(C) The total number of tumors observed in the
colon of separately housed and co-housed mice
80 days after injection of AOM.
(D) Representative images of colons in (C).
Each column represents one mouse (A). Each
symbol represents one mouse (B and C). Data
represent one experiment (A and B) or pooled from
two independent experiments (C and D) (mean and
SEM in [C]). *p < 0.05; ****p < 0.0001. One-way
ANOVA (C). See also Figure S5.
twice with 2.5% DSS, and mice were sacrificed on
day 80. For Day 8 samples, mice were injected with
AOM, and after 5 days, they were fed with 3% DSS
for 3 days before mice were sacrificed. For day 14
samples, mice were injected with AOM, and after
5 days, they were fed with 3% DSS for 6 days.
Mice were then fed with regular water for 3 days
and sacrificed. For co-housing experiments, equal numbers of female WT
and female Aim2–/– mice were housed in the same cage for 4 weeks. Mice
were then housed separately prior to AOM injection and remained separated
over the course of the experiment. To induce aberrant Wnt signaling, tamox-
ifen induction was performed on 2-month-old mice by oral gavage with
200 ml tamoxifen (20 mg/ml) in corn oil for 2 days.
Histology and Microscopy Analysis
Colon tissues were fixed in 10% formalin, embedded in paraffin, sectioned,
and stained with H&E. The number of proliferating cells in the intestinal epithe-
lium was detected by immunoperoxidase staining for thymidine analog
50-bromo-20deoxyuridine (BrdU) as described previously (Rakoff-Nahoum
et al., 2004). In brief, 1mg/ml BrdU in PBSwas injected intraperitoneally. Colon
tissues were collected after 2 hr and fixed in 10% neutral buffered formalin
and embedded in paraffin. Immunohistochemistry was performed using
the in situ BrdU staining kit according to manufacturer’s instructions (BD
Bioscience, 550803). Ki67 (NBP1-40684, Novus), AKT (4691, Cell Signaling),
p-AKT (Ser473; 4060, Cell Signaling), and c-Myc (5605, Cell Signaling) staining
were performed using antibodies according to the manufacturers’ instruc-
tions. Tissues were counterstained with hematoxylin. The number of Ki67- or
BrdU-positive cells per crypt in each animal was counted (at least 18–20 crypts
per mouse). To visualize goblet cells, colon tissues were stained with PAS and
Alcian blue. The number of goblet cells per crypt was enumerated.
For nLacZ analysis and GFP microscopy, tissues were perfused and fixed
in 2% paraformaldehyde overnight, cryo-protected, and frozen in OCT.
Sections were stained for b-galactosidase or examined for GFP signal.
For b-galactosidase staining, frozen sections were washed in PBS for
5 min and incubated in the dark in standard b-galactosidase substrate
(5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 1 mg/ml
X-gal, 2 mM MgCl2, 0.01% sodium deoxycholate, and 0.02% NP-40
in PBS) for 4 hr at 37C. Sections were then rinsed and counterstained
by Nuclear Fast Red (Vector, H-3403).
Real-Time qRT-PCR
RNAwas isolated using Trizol and converted into cDNA. Gene expression was
assessed using 23 Sybrgreen kit according to themanufacturer’s instructions
(Applied Biosystems). Sequences for qRT-PCR primers are listed in Table S1.
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The cancer survey cDNA array was used to evaluate human AIM2 gene
expression in tumor tissues, which was performed according to the manufac-
turer’s instructions (Origene).
Cytokine Measurement
Cytokines in colon and sera were measured by ELISA according to manufac-
turers’ instructions. The IL-18 ELISA was from eBioscience. Multiplex ELISAs
were used for all other cytokines (Millipore).
Western Blotting
Proteins were extracted from colon tissues using RIPA lysis buffer supple-
mented proteinase and phosphatase inhibitors (Roche). Samples were
resolved in 12%–15% SDS-PAGE and transferred onto PVDF membranes.
Blocking was performed in 5% milk for 1 hr, and membranes were incubated
in primary antibodies overnight at 4C. Membranes were incubated with HRP-
conjugated secondary antibody for 1 hr, and proteins were visualized using
ECL substrate (ThermoScientific). The primary antibodies were caspase-1
p10 (1:500 dilution, sc-515, Santa Cruz), p-ERK (1:1,000, 9101, Cell Signaling),
ERK (1:1,000, 9102, Cell Signaling), p-IkBa (1:1,000, 9241, Cell Signaling), IkBa
(1:1,000, 9242, Cell Signaling), HIF-1a (1:1,000, 3716, Cell Signaling), p-AKT
Ser473 (1:1,000, 9271, Cell Signaling), AKT (1:1,000, 4691, Cell Signaling),
p-PTEN (1:1,000, 9554, Cell Signaling), PTEN (1:1,000, 9552, Cell Signaling),
c-Myc (1:1,000, 5605, Cell Signaling), caspase-3 (1:1,000, 9662, Cell
Signaling), cleaved caspase-3 (1:1,000, 9661, Cell Signaling), caspase-7
(1:1,000, 9492, Cell Signaling), cleaved caspase-7 (1:1,000, 9491, Cell
Signaling), and GAPDH (1:40,000, 5174, Cell Signaling).
Microarray Analysis
RNA was extracted from colon tissues of WT and Aim2/ mice after 14 days
post-AOM injection. Mouse Gene 2.0 (Affymetrix) was used to examine the
gene expression profiles. GSEA software (Broad Institute) was used to analyze
the relevant signaling pathways.
Colon Organoid Culture
Mouse colon stem cells were cultured as previously described with modifica-
tions (Yui et al., 2012). Briefly, mice were perfused with prewarmed 30 mM
EDTA in PBS. Colon was removed and rinsed with PBS. Colonic mucosa
was scraped from the muscle layer and kept in 10 mM EDTA in PBS on ice
and incubated in a shaker at 350 RPM for 15 min at 4C. Dissociated colonic
crypts were vigorously suspended. Cells were filtered through a 70 mm cell
strainer, mixed with Matrigel (BD Bioscience, 354230) and plated in 60 mm
plates. The culture medium consisted of Advanced DMEM/F12 supplemented
with B27, N2, N-Acetylcysteine, Gastrin (10 nM), and growth factors, including
50 ng/ml EGF, 1 mg/ml R-spondin1, 100 ng/ml Noggin, 100 ng/ml FGF10, and
Wnt3A conditioned media (Willert et al., 2003).
Bone Marrow Chimeras
Mice were subjected to split-dose irradiation, first with a 350 rad dose, fol-
lowed by a 950 rad dose 24 hr later. 2 hr after the second dose of irradiation,
mice were injected intravenously with 107 bone marrow cells from the femur
and tibia of donor mice. The following four groups of chimeric mice were
generated: WT/ WT (CD45.1-expressing WT cells into CD45.2-expressing
WT mice), Aim2//WT (CD45.2-expressing Aim2/ cells into CD45.1-ex-
pressingWTmice), WT/ Aim2/ (CD45.1-expressingWT cells into CD45.2-
expressing Aim2/ mice) and Aim2/ / Aim2/ (CD45.2-expressing
Aim2/ cells into CD45.2-expressing Aim2/ mice). The reconstitution rate
evaluated 6weeks after bonemarrow transfer was determined by flow staining
of CD45.1 and CD45.2 in blood leukocytes, which was at least 95%.
Universal Sequencing of the Gut Microbiota
Genomic DNA from feces were extracted by QiAMP DNA stool Mini Kit
(QIAGEN) and used for 16S rRNA gene sequencing. Libraries were prepared
by amplification of the 16S v4 domain according to themanufacturer’s instruc-
tions (Bioo Scientific Corporation). Paired-end 150 cycle sequencing was
performed on a MiSeq using 300 cycle v2 sequencing kits according the man-
ufacturer’s instructions (Illumina) with the following modifications: a phiX
library was spiked in at10%, and library specific sequencing primers were
added to the Illumina primer wells as specified by the manufacturer (Bioo
Scientific Corporation).
Statistical Analysis
Statistical significance was determined by Student’s t test or ANOVA; p < 0.05
was considered statistically significant where *p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001.
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO:
GSE69436. The study number for the microbiota sequences reported in this
paper is NCBI: SRP059020.
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